Tous Actualités
Suivre
Abonner Janssen-Cilag AG

Janssen-Cilag AG

Driving Change in Mental Health Through Science and Community

Beerse, Belgium (ots/PRNewswire)

Today, Janssen-Cilag
are celebrating their 50 year commitment to researching and
developing innovative medicines to help improve the lives of people
with mental health problems. Back in 1958, the late Dr. Paul Janssen
developed one of the first anti-psychotic drugs, which proved to be a
real breakthrough in the treatment of schizophrenia and hailed the
onset of a new era for patients being treated outside of
institutions. Over the past 50 years, Janssen-Cilag have developed
several new compounds in the field of mental health, constantly
raising the bar in treatment expectations for many patients.
However, much more still needs to be done in the area of mental
health. Each patient is different and there is no drug or treatment
that fits all, hence the need for continued cutting edge research and
development to not only provide new medications but create tailor
made treatment options for patients in the future.
Today, the company wishes to pay tribute to this heritage in
psychiatry, but also wants to look ahead and showcase its future
developments in the treatment of diseases of the central nervous
system. Now more than ever, Janssen-Cilag's aim and ultimate target
remains to fulfill unmet medical needs and to ensure the well-being
of patients and their families.
The celebration which takes place at Janssen Pharmaceutica in
Beerse (Belgium) on Thursday, October 2nd, includes exhibitions and
education for the company's employees and an academic session in the
evening for psychiatrists and others interested in the field of
mental health.
History
Janssen-Cilag originates from the merger of the pharmaceutical
groups within Johnson & Johnson (J&J), namely Janssen and Cilag. Dr
Paul Janssen established Janssen Pharmaceutica in 1953 in Belgium.
Cilag (an acronym of Chemical Industry Laboratory AG) was founded in
Switzerland (Schaffhausen) in 1936.
More information about the company can be found at
http://www.janssen-cilag.com

Contact:

Sue Silk, Manager, CNS Communications EMEA, Tel: +44-1494-553955,
E-mail: ssilk@its.jnj.com

Plus de actualités: Janssen-Cilag AG
Plus de actualités: Janssen-Cilag AG